Relation Between Serum Zinc Level, Prostatic Size and PSA Level in Benign Prostatic Hyperplasia of Libyan Patients
DOI:
https://doi.org/10.71147/2axpdz83Keywords:
Benign Prostatic Hyperplasia, Prostatic Specific Antigen, Serum Zinc, Prostatic Size.Abstract
Background: Benign prostatic hyperplasia (BPH) is the most common benign tumour of the prostate. BPH usually appears after the age of 40 and progresses slowly. The enlarged prostate may compress the urethra, which passes through the middle of the prostate, preventing urine from flowing from the bladder to the outside. Complete obstruction can develop if BPH is a huge enlargement. Aim of the Study: Study the relation between serum zinc and PSA in Derna City BPH patients. Materials and Methods: The case-control study lasts seven months, from April to the end of October, at Al-wahda Teaching Hospital in Derna City, Libya. It entailed gathering 60 blood samples, which were separated into two groups. The first group (A) consisted of 40 patients with benign prostatic hyperplasia ranging in age from 45 to 75 years which were classified into three sub-groups (45-54), (55-64), (66-75); while the second group (B) consisted of 20 be healthy males aged 45 to 75 years as same classified of sub-groups of patients. All participants in this study provided diagnosis permission. the patient's prostate volumes (PV) were equal to or more than 58 millilitres. Radiologists with competence in the department used transabdominal ultrasound equipment manufactured in Germany by Siemens to figure out how big the prostate gland is. Both groups had their serum zinc and PSA levels measured by ELISA (Enzyme-Linked Immunosorbent Assay). Results: The study showed that the mean prostate size was elevated significantly in the BPH group (64.36 ± 2.9 cc) as compared with the control group (22.44 ± 2.1 cc) (P=0.001). There is a significant increase in the PSA levels of benign prostatic hyperplasia patients, (3.57±0.57ng/ml), as compared with control subjects, (1.14±0.278 ng/ml) (P=0.001). There is a significant reduction in the serum zinc concentration of benign prostatic hyperplasia patients, (64.57±6.73ng/ml), as compared with control subjects, (110.6±12.37) (p=0.01). Conclusion: Benign prostatic hyperplasia patients of all ages had considerably higher serum PSA than age-matched healthy controls. Benign prostatic hyperplasia patients of all ages had markedly lower serum zinc than age-matched healthy controls. Prostate size is greater in benign prostatic hyperplasia patients than age-matched healthy controls.
References
Alawad AA, Younis FH, Eltoum AM, & Abdelgani SA. (2014). Serum prostate-specific antigen as a predictor of prostate volume in Sudanese patients with benign prostatic hyperplasia. Age (year). 51:62-72.
Amis ES. (1994). Anatomy and physiology of the prostate. In: Lang EK. Editor. Radiology of the Lower Urinary Tract. Heidelberg: Springer; 167–9.
Anyimba SK, Amu OC, Nnabugwu II, Okoh AD, & Nwachukwu CD. (2023). Prevalence and Distribution of Postvoid Residual Urine Volume in a Hospital-Based Sample of Men with Symptomatic Benign Prostatic Hyperplasia. Niger J Clin Pract. 26:1839-43.
Auffenberg GB, Helfand BT, & McVary KT. (2009). Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am. 36:443.
Aydin A. Sarafinovska Z.A., Sayal A., Eken A., Erdem O, & Erten K...(2006). Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatichyperplasia. Clin Biochem 39, 176–9.
Bangma C H, Niemer A Q, Grobbee D E, Schröder F H.(1996). Transrectal ultrasonic volumetry of the prostate: in vivo comparison of different methods Prostate. 28:107-10.
Boyle P, Gould AL, & Roehrborn CG. (1996). Prostate volume pre- dicts outcome of treatment of benignprostatic hyperplasia with finasteride: meta-analysis of randomised clinical trials. Urology.48:398–405.
Chen G., Wu L., Wu Y., & Zhu J. (2015).Content Change of Zinc and Cadmium in Serum of Patients with Prostate Cancer and its Clinical Significance. J. Clin. Urol. 30:439–41.
Chenven E S, Glazier D B, Krisch E B, Diamond S M, & Marmar J L.(2001) Evaluation of prostate volume by transrectal ultrasonography for use in a brachytherapy program. Urology. 58:753–7.
Christudoss P., Selvakumar R., Fleming J. J. & Gopalakrishnan G. (2011). Zinc status of patients with benign prostatic hyperplasia and prostate carcinoma. Indian J Urol. 27, 14–8.
Cinislioglu, A. E., Demirdogen, S. O., Cinislioglu, N., Altay, M. S., Sam, E., & Akkas, F. (2022). Variation of serum PSA levels in COVID-19 infected male patients with benign prostatic hyperplasia (BPH): a prospective cohort studys. Urology, 159, 16-21.
Costello L.C., & Franklin R.B. (2006).The Clinical Relevance of the Metabolism of Prostate Cancer; Zinc and Tumor Suppression: Connecting the Dots. Mol. Cancer. 5:17.
Costello L.C., & Franklin R.B. (2011). Zinc is decreased in Prostate Cancer: An Established Relationship of Prostate Cancer! J. Biol. Inorg. Chem. 16:3–8.
Costello L.C., & Franklin R.B. (2016). A Comprehensive Review of the Role of Zinc in Normal Prostate Function and Metabolism; and its Implications in Prostate Cancer. Arch. Biochem. Biophys. 611:100–12.
Ene, C., Ene, C. D., Nicolae, I., Coman, L., & Coman, O. A. (2014). Zinc and androgen hormones in benign prostatic hyperplasia. Medicina. 21(2), 106-11.
Erdogan, A., Polat, S., Keskin, E., & Turan, A. (2020). Is prostate volume better than PSA density and free/total PSA ratio in predicting prostate cancer in patients with PSA 2.5–10 ng/mL and 10.1–30 ng/mL? The Aging Male. 23(1), 59-65.
Feng, P., Li, T. L., Guan, Z. X., Franklin, R. B., & Costello, L. C. (2002).Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. The Prostate52 (4), 311-8.
Hendrikx, A.J., van Helvoort-van Dommelen C A, van Dijk M A, Reintjes A G, & Debruyne F M (1989).Ultrasonic determination of prostatic volume: a cadaver studyUrology. 34:123-5
Ji K., Zhang L., Shao Y., Tian Y., Liang Z., Liu Y. (2007). Significance of trace elements copper and zinc change in the serum of patients with prostate cancer. Chinese Journal of Andrology. 21, 9–11.
Kaba M., Pirincci N., Yuksel M.B., Gecit I., Gunes M., Ozveren H., Eren H., & Demir H. (2014). Serum Levels of Trace Elements in Patients with Prostate Cancer. Asian Pac. J. Cancer Prev. 15:2625–9.
Laczko I., Hudson D.L., Freeman A., Feneley M.R., & Masters J.R. (2005). Comparison of the Zones of the Human Prostate with the Seminal Vesicle: Morphology, Immunohistochemistry, and Cell Kinetics. Prostate. 62:260–6.
Lee S.E., Chung J.S., Han B.K., Moon K.H., Hwang S.I., & Lee H.J. (2008). Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia. Urology. 71:395–8.
Lieber M M, Jacobsen S J, Roberts R O, Rhodes T, & Girman C J (2001). Prostate volume and prostate-specific antigen in the absence of prostate cancer: a review of the relationship and prediction of long-term outcomes. Prostate. 49:208–12.
Liu Y. Y. (1993). The change of zinc, androgen metabolism in patients with benign prostatic hyperplasia. Chin J Endocrinol Metab. 9, 30–311.
Liu, J., Dong, B., Qu, W., Wang, J., Xu, Y., & Yu, S. (2020).Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone. Scientific Reports. 10(1), 5157.
Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Ember- ton M, & de la Rosette JJMCH.(2007). EAU 2004 guidelines on European urology 5 1: 1 6 4 5 –5 3.
Mahde, S. H., Sarhat, E. R., Salim, J. K., Thuraia, R. S., & Kasim, S. (2020). Characteristic Abnormalities in Serum Biochemistry In Patients With Breast Cancer. Sys Rev Pharm. 11(11), 1967-77.
Marberger M J, Andersen J T , Nickel J C , Malice M P , Gabriel M ,& Pappas F. (2000). Prostate volume and serum prostate- specific antigen as predictors of acute urinary retention. Eur Urol . 38:563–8.
McConnell JD. (1991). the pathophysiology of benign prostatic hyperplasia. J Androl. 12:356–63.
McNeal J. (1990). Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am. 17:477–86.
Mobley D, Feibus A, & Baum N. (2015). Benign prostatic hyperplasia and urinary symptoms: evaluation and treatment. Postgrad Med. 127:301–7.
Morote J., Encabo G., Lopez M., & de Torres I.M. (2002). Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable? Eur Urol. 38:91–5.
Nawal, A. Al-Madany, & Entedhar R. Sarhat. (2018).Determination of Some Biochemical Parameters of Patients with Hepatitis B in Kirkuk City. Kirkuk University Journal/Scientific Studies (KUJSS). 13(2), 139-48.
Ogunlewe J. O. & Osegbe D. N. (1998). Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostate. Cancer. 63, 1388–92.
Onyema-iloh B.O., Meludu S.C., Iloh E., Nnodim J., Onyegbule O.,& Mykembata B.(2015). Biochemical Changes in Some Trace Elements, Antioxidant Vitamins and their Therapeutic Importance in Prostate Cancer Patients. Asian J. Med. Sci. 6:95–7.
Park S.Y., Wilkens L.R., Morris J.S., Henderson B.E., & Kolonel L.N. (2013). Serum Zinc and Prostate Cancer Risk in a Nested Case-Control Study: The Multiethnic Cohort. Prostate. 73:261–6.
Patel ND & Parsons JK. (2014). Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Ind J Urol. 30:170–6.
Putra IB, Hamid AR, Mochtar CA, & Umbas R.(2014). Relationship of age, prostate-specific antigen, and prostate volume in indonesian men with benign prostatic hyperplasia. BJU Int 114.
Rodríguez-López, M.R., Baluja-Conde IB, & Bermúdez-Velásquez S. (2007). Patologías benignas de la prostate prostatitis with hyperplasia benign. Rev Biomed. 18:47–59.
Roehrborn C & McConnell J. (2002). Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh P, Retik A, Vaughan E, Wein A. editors. Campbell's Urology. 8th ed Philadelphia, PA: Saunders; 1297–336.
Roehrborn C G, Boyle P, Gould A L, & Waldstreicher J. (1999). Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 53:581-9.
Roehrborn CG. (2005). benign prostatic hyperplasia: an overview. Rev Urol. 7(Suppl 9):3–14.
Roehrborn C G, Girman C J, Rhodes T, Hanson K A, Collins G N, & Sech S M. (1997). Correlation between prostate sizes estimated by digital rectal examination and measured by transrectal ultrasound.Urology. 49:548-57.
Sapota A., Daragó A., Taczalski J., & Kilanowicz A. (2009). Disturbed Homeostasis of Zinc and other Essential Elements in the Prostate Gland Dependent on the Character of Pathological Lesions. Biometals. 22:1041–9.
Sarhat, E. R. (2015).Study the levels of Leptin, and Adiponectin with Paraoxonase in Obese Individuals (male & female). Tikrit Journal of Pure Science. 20(2), 14-20.
Sasanka KB, Simanta JN, Rajeev TP, Saumar JB, Phanindra MD. (2015).. Correlation of age, prostate volume, serum prostate-specific antigen, and serum testosterone in Indian, benign prostatic hyperplasia patients. Uro Today Int J. 5.
Sauer, A. K., Vela, H., Vela, G., Stark, P., Barrera-Juarez, E., & Grabrucker, A. M. (2020). Zinc deficiency in men over 50 and its implications in prostate disorders. Frontiers in Oncology. 10, 553161.
Shao WH, Zheng CF, Ge YC, Chen XR, & Zhang BW. (2023). Age-related changes for the predictors of benign prostatic hyperplasia in Chinese men aged 40 years or older. Asian J Androl. 25:132-6.
Singh, H., Kaur, M., & Kaur, H. (2019).Establishment and correlation of age specific reference range of psa and psa density in patients of benign prostatic hyperplasia. GMC Patiala Journal of Research and Medical Education. 2(1), 45-50.
Sztalmachova M., Hlavna M., Gumulec J., Holubova M., Babula P., Balvan J., Sochor J., Tanhauserova V., Raudenska M., & Krizkova S. (2012). Effect of Zinc (II) Ions on the Expression of Pro- and Anti-Apoptotic Factors in High-Grade Prostate Carcinoma Cells. Oncol. Rep. 28:806–14.
Tawfeq, M., & Sarhat, E. (2023).METFORMIN EFFECTS ON NEUREGULIN-1 IN POLYCYSTIC OVARIAN WOMEN. Georgian Medical News. 4(337), 56-62.
Terris, M.K. & Stamey, T.A. (1991). Determination of prostate volume by transrectal ultrasoundJ Urol. 145:984-987
Tong S , Cardinal H N, McLoughlin R F, Downey D B, & Fenster A.(1998). Intra- and inter-observer variability and reliability of prostate volume measurement via two- dimensional and three-dimensional ultrasound imaging. Ultrasound Med Biol; 24:673–81.
Torp-Pedersen, S. Juul, N. & Jakobsen, H. (1988).Transrectal prostatic ultrasonography. Equipment, normal findings, benign hyperplasia and cancerScand. J Urol Nephrol. 107:19-25
Tsukamoto T., Masumori N., Rahman M., & Crane M.M. (2007). Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally. Int J Urol. 14:321–4.
Wakwe V.C., Odum E.P., & Amadi C. (2019). The Impact of Plasma Zinc Status on the Severity of Prostate Cancer Disease. Investig. Clin. Urol. 60:162–8.
Yao D., Johnes A., & Fragmann C. (1977).The Content of Serum Zinc Concentration in Prostate Disease. Int. J. Surg. 4:225–7.
Yousif, O. K., Abdalla, B. E., Ahmed, M. A. M., Taha, S. M., Ebraheem, A. A. S., & Ahmed, E. A. (2023). Study on Early Prostate Cancer Antigen (EPCA) and existent prostate cancer risk factors, Sudan: A case-control study. World Journal of Advanced Research and Reviews, 17(3), 736-46.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Zeid Saleh Sasi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
